Search results
Aug 6, 2015 · A non–vitamin K antagonist oral anticoagulant, dabigatran etexilate (dabigatran) is an oral thrombin inhibitor that is licensed for the prevention of stroke in patients with...
Oct 28, 2019 · Idarucizumab (Praxbind, Boehringer Ingelheim) is a humanized monoclonal antibody fragment with structural analogies with thrombin that specifically binds dabigatran with high affinity, forming complexes cleared by the kidneys.
May 2, 2013 · Here, we present data on the identification, humanization, and in vitro pharmacology of an antidote for dabigatran (aDabi-Fab). The X-ray crystal structure of dabigatran in complex with the antidote reveals many structural similarities of dabigatran recognition compared with thrombin.
Aug 6, 2019 · Dabigatran binds to idarucizumab with 350 times greater affinity than for factor II. 5, 44 It is the only U.S. Food and Drug Administration (FDA)-approved antidote for bleeding related to dabigatran. It is manufactured in 2.5 gram (g) vials, and it is administered as a 5 g total dose intravenously.
May 24, 2016 · Licensed oral anticoagulants that are used in the UK include warfarin, and the NOACs apixaban, dabigatran etexilate, edoxaban and rivaroxaban. The most common adverse effect of anticoagulants is bleeding, ranging from mild events to serious and fatal haemorrhage.
Jan 12, 2022 · Dabigatran reversal. Idarucizumab is a humanised monoclonal antigen binding fragment (Fab) antibody that binds dabigatran with 350 times more avidity than thrombin, and rapidly reverses its anticoagulant effect. It has no intrinsic activity in the coagulation system, providing immediate, complete and sustained reversal of the dabigatran effect. 18
Aug 3, 2017 · Idarucizumab is a humanized monoclonal antibody fragment that binds dabigatran with high affinity and specificity and rapidly reverses its anticoagulant activity. 1 Idarucizumab has been licensed...
